These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33096620)

  • 1. Distinct Expression Patterns of VEGFR 1-3 in Gastroenteropancreatic Neuroendocrine Neoplasms: Supporting Clinical Relevance, but not a Prognostic Factor.
    Bösch F; Altendorf-Hofmann A; Jacob S; Auernhammer CJ; Spitzweg C; Boeck S; Schubert-Fritschle G; Werner J; Kirchner T; Angele MK; Knösel T
    J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33096620
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Clinical Significance of PD-L1/PD-1 Expression in Gastroenteropancreatic Neuroendocrine Neoplasia.
    Wang C; Yu J; Fan Y; Ma K; Ning J; Hu Y; Niu W; Dong X; Wu Y; Li E; Dong D
    Ann Clin Lab Sci; 2019 Sep; 49(4):448-456. PubMed ID: 31471333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia.
    Bösch F; Brüwer K; Altendorf-Hofmann A; Auernhammer CJ; Spitzweg C; Westphalen CB; Boeck S; Schubert-Fritschle G; Werner J; Heinemann V; Kirchner T; Angele M; Knösel T
    Endocr Relat Cancer; 2019 Mar; 26(3):293-301. PubMed ID: 30608901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
    Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
    Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of PD-L1 expression in a large set of gastroenteropancreatic neuroendocrine tumours and correlation with clinicopathological data.
    Rösner E; Kaemmerer D; Sänger J; Lupp A
    Transl Oncol; 2022 Nov; 25():101526. PubMed ID: 36067541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic characteristics and prognosis of gastroenteropancreatic neuroendocrine neoplasms: a multicenter study in South China.
    Fang C; Wang W; Zhang Y; Feng X; Sun J; Zeng Y; Chen Y; Li Y; Chen M; Zhou Z; Chen J
    Chin J Cancer; 2017 Jun; 36(1):51. PubMed ID: 28637502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
    Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
    BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1 Expression and Immune Cell Infiltration in Gastroenteropancreatic (GEP) and Non-GEP Neuroendocrine Neoplasms With High Proliferative Activity.
    Ferrata M; Schad A; Zimmer S; Musholt TJ; Bahr K; Kuenzel J; Becker S; Springer E; Roth W; Weber MM; Fottner C
    Front Oncol; 2019; 9():343. PubMed ID: 31134150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm.
    Wang Y; Chen Y; Li X; Hu W; Zhang Y; Chen L; Chen M; Chen J
    BMC Cancer; 2018 Jun; 18(1):691. PubMed ID: 29940892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pathological characteristics and survival analysis of 355 patients with gastroenteropancreatic neuroendocrine neoplasms].
    Li Y; Wang YF; Tan BB; Er LM; Zhao Q; Fan LQ; Zhang ZD; Liu Y
    Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):426-431. PubMed ID: 32482035
    [No Abstract]   [Full Text] [Related]  

  • 11. Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms.
    Milione M; Miceli R; Barretta F; Pellegrinelli A; Spaggiari P; Tagliabue G; Centonze G; Paolino C; Mangogna A; Kankava K; Pusceddu S; Giacomelli L; Corti A; Cotsoglou C; Mazzaferro V; Sozzi G; de Braud F; Pruneri G; Anichini A
    J Pathol Clin Res; 2019 Oct; 5(4):217-226. PubMed ID: 31136102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Interplay of Four Main Pathways Recomposes Immune Landscape in Primary and Metastatic Gastroenteropancreatic Neuroendocrine Tumors.
    Lou X; Gao H; Xu X; Ye Z; Zhang W; Wang F; Chen J; Zhang Y; Chen X; Qin Y; Yu X; Ji S
    Front Oncol; 2022; 12():808448. PubMed ID: 35664743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathological features and survival analysis of gastroenteropancreatic neuroendocrine neoplasms: a retrospective study in a single center of China.
    Jiao X; Li Y; Wang H; Liu S; Zhang D; Zhou Y
    Chin J Cancer Res; 2015 Jun; 27(3):258-66. PubMed ID: 26157322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gastroenteropancreatic neuroendocrine neoplasms: a 10-year experience of a single center.
    Lewkowicz E; Trofimiuk-Müldner M; Wysocka K; Pach D; Kiełtyka A; Stefańska A; Sowa-Staszczak A; Tomaszewska R; Hubalewska-Dydejczyk A
    Pol Arch Med Wewn; 2015; 125(5):337-46. PubMed ID: 25924181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors.
    Sampedro-Núñez M; Serrano-Somavilla A; Adrados M; Cameselle-Teijeiro JM; Blanco-Carrera C; Cabezas-Agricola JM; Martínez-Hernández R; Martín-Pérez E; Muñoz de Nova JL; Díaz JÁ; García-Centeno R; Caneiro-Gómez J; Abdulkader I; González-Amaro R; Marazuela M
    Sci Rep; 2018 Dec; 8(1):17812. PubMed ID: 30546030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
    Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
    BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs.
    Kim ST; Ha SY; Lee S; Ahn S; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim KM; Park YS
    J Cancer; 2016; 7(5):484-9. PubMed ID: 26958083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical Study of Mitosis-regulatory Proteins in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Briest F; Wang Y; Arsenic R; Elezkurtaj S; Berg E; Greshake S; Lock AC; Hörsch D; Arnold CN; Hummel M; Siegmund B; Grabowski P
    Anticancer Res; 2018 Jul; 38(7):3863-3870. PubMed ID: 29970506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of IMP3 as a marker for predicting poor outcome in gastroenteropancreatic neuroendocrine neoplasms.
    Er LM; Li Y; Wu ML; Zhao Q; Tan BB; Wang XL; Wang SJ
    Oncol Lett; 2017 Apr; 13(4):2391-2396. PubMed ID: 28454409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors of patients with gastroenteropancreatic neuroendocrine neoplasms.
    Huang PY; Tsai KL; Liang CM; Tai WC; Rau KM; Wu KL; Huang CC; Chuah SK
    Kaohsiung J Med Sci; 2018 Nov; 34(11):650-656. PubMed ID: 30392572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.